HK-listed Simcere Pharmaceutical gains on clinical trial approval for cancer drug

Simcere Pharmaceutical

10/04/2025 06:09

** Shares of Simcere Pharmaceutical Group Ltd 2096.HK jump 5.5% to HK$8.07, their biggest intraday pct gain since February 18

** Stock on course for a third consecutive session of gains, if current trend holds

** Simcere Pharmaceutical says its anti-tumor drug candidate - SIM0686 - has obtained a Clinical Trial Approval, issued by China's National Medical Products Administration (NMPA)

** SIM0686 is an FGFR2b Antibody-Drug Conjugate for treatment of gastric cancer and lung cancer

** Hong Kong's healthcare index .HSCIH rises 2.1%, Hang Seng Index .HSI rises 1.8%

** Stock up 7.8% YTD

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))